Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Equivalence Trial of FYB206 vs Keytruda in Resected Melanoma
NCT06551064Phase 1Completed
- Sponsor
- Formycon AG
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 1, randomised, double-blind trial of FYB206 in melanoma (2 arms), sponsored by Formycon AG. Primary endpoint: Area Under the Concentration-Time Curve Over the Dosing Interval at 126 days. Started Jul 2024; status: completed.
02
Drugs
FYB206
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06551064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06551064.